Literature DB >> 22936010

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Nathalie Le Bastard1, Els Coart, Hugo Vanderstichele, Eugeen Vanmechelen, Jean-Jacques Martin, Sebastiaan Engelborghs.   

Abstract

Combined analysis of the Alzheimer's disease (AD) biomarkers amyloid-β(1-42) (Aβ(1-42)), total tau (T-tau), and hyperphosphorylated tau (P-tau(181P)) in cerebrospinal fluid (CSF) reduces the uncertainty associated with clinical dementia diagnosis. The present study evaluated the diagnostic accuracy of the CSF biomarker concentrations obtained with a multi-analyte Luminex assay (INNO-BIA AlzBio3) in comparison to single-analyte ELISA tests (INNOTEST). Data from 66 pathologically-confirmed dementia patients (51 AD and 15 non-AD) and 95 controls were included. Cut-off values were determined for each individual biomarker determined using both methods for different diagnostic challenges (dementia-controls; AD-controls; AD-non-AD). Comparing the diagnostic accuracy of individual cut-off values between INNO-BIA and INNOTEST, no relevant differences could be identified. Logistic regression was used in addition to identify the best combination of predictor variables (biomarkers). Discrimination of dementia patients from controls using Aβ(1-42) and T-tau yielded a diagnostic accuracy of 0.87 and 0.90 for INNO-BIA and INNOTEST, respectively. Discriminating AD patients from controls, the diagnostic accuracy was 0.90 and 0.93 for INNO-BIA and INNOTEST, respectively. Optimal discrimination of AD and non-AD patients was achieved by combining Aβ(1-42) and P-tau(181P) (diagnostic accuracy = 0.86). In conclusion, which AD biomarkers or combination thereof are most informative is dependent on the differential diagnosis, but the clinical value of these markers in each of the differential diagnoses is independent of the method by which concentrations are determined. Since the clinical value of the ELISA (INNOTEST) and Luminex (INNO-BIA) tests is comparable, further research to select the most suitable analytical platform for routine CSF biomarker measurements is needed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22936010     DOI: 10.3233/JAD-2012-121246

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  19 in total

1.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

Authors:  Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

2.  Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics.

Authors:  Joëlle Rosseels; Jeff Van den Brande; Marie Violet; Dirk Jacobs; Pierre Grognet; Juan Lopez; Isabelle Huvent; Marina Caldara; Erwin Swinnen; Anthony Papegaey; Raphaëlle Caillierez; Valerie Buée-Scherrer; Sebastiaan Engelborghs; Guy Lippens; Morvane Colin; Luc Buée; Marie-Christine Galas; Eugeen Vanmechelen; Joris Winderickx
Journal:  J Biol Chem       Date:  2014-12-24       Impact factor: 5.157

3.  Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease.

Authors:  Catherine Pan; Ané Korff; Douglas Galasko; Carmen Ginghina; Elaine Peskind; Ge Li; Joseph Quinn; Thomas J Montine; Kevin Cain; Min Shi; Jing Zhang
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 4.  Role of HIV in amyloid metabolism.

Authors:  Mario Ortega; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-10       Impact factor: 4.147

5.  CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.

Authors:  Jon B Toledo; Ane Korff; Leslie M Shaw; John Q Trojanowski; Jing Zhang
Journal:  Acta Neuropathol       Date:  2013-06-29       Impact factor: 17.088

Review 6.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

7.  Increased inflammation in BA21 brain tissue from African Americans with Alzheimer's disease.

Authors:  Sherry A Ferguson; Vijayalakshmi Varma; Daniel Sloper; John J Panos; Sumit Sarkar
Journal:  Metab Brain Dis       Date:  2019-12-10       Impact factor: 3.584

Review 8.  Diagnosis of neurodegenerative dementia: where do we stand, now?

Authors:  Giulia M Sancesario; Sergio Bernardini
Journal:  Ann Transl Med       Date:  2018-09

9.  Alzheimer's disease: a step closer to understanding type 3 diabetes in African Americans.

Authors:  Sherry A Ferguson; John J Panos; Daniel Sloper; Vijayalakshmi Varma; Sumit Sarkar
Journal:  Metab Brain Dis       Date:  2021-05-22       Impact factor: 3.584

10.  Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β1-42 and total tau.

Authors:  Mirjana Babić; Zeljka Vogrinc; Andrea Diana; Nataša Klepac; Fran Borovečki; Patrick R Hof; Goran Simić
Journal:  Transl Neurosci       Date:  2013-06       Impact factor: 1.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.